Role of extended release quetiapine in the management of bipolar disorders

Neuropsychiatric Disease and Treatment

Volumn 6, Issue 1, 2010, Pages 29-35

  Al Jurdi, Rayan K ^a,b   Dixit, Lena A ^a   Sajatovic, Martha ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bipolar disorder; Quetiapine XR

Indexed keywords

LITHIUM; PLACEBO; PROLACTIN; QUETIAPINE; TRIACYLGLYCEROL; VALPROATE SEMISODIUM;

ADJUVANT THERAPY; AREA UNDER THE CURVE; BIPOLAR DISORDER; BIPOLAR I DISORDER; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FATIGUE; HUMAN; INCREASED APPETITE; LIVER FUNCTION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MUSCLE HYPERTONIA; NAUSEA; OUTCOME ASSESSMENT; OXIDATION; PHARMACODYNAMICS; PROLACTIN BLOOD LEVEL; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SULFOXIDATION; SYSTOLIC BLOOD PRESSURE; TABLET; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; XEROSTOMIA;

EID: 77950809193     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s4903     Document Type: Review

References (32)

1. Grant BF, Stinson FS, Hasin DS, et al. Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2005;66:1205-1215.
2. Dinan TG. Lithium in bipolar mood disorder [editorial]. BMJ. 2002;324:989-990.
3. Fountoulakis KN, Vieta E, Siamouli M, et al. Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder. Ann Gen Psychiatry. 2007;6:27.
4. Sajatovic M, Madhusoodanan S, Fuller MA, et al. Risperidone for bipolar disorders. Expert Rev Neurother. 2005;5:177-187.
5. Pope HG, McElroy SL, Keck PE, Hudson JI. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry. 1991;48:62-68.
6. Bowden CL, Brugger AM, Swann AC. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA. 1994;271:918-924.
7. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM. Lamotrigine: a review of its use in bipolar disorder. Drugs. 2003;63:2029-2050.
8. McElroy SL, Keck PE. Pharmacologic agents for the treatment of acute bipolar mania. Biol Psychiatry. 2000;48:539-557.
9. Sajatovic M, Valenstein M, Blow FC, Ganoczy D, Ignacio RV. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord. 2006;8(3):232-241.
10. Depp C, Ojeda VD, Mastin W, et al. Trends in use of antipsychotics and mood stabilizers among Medicaid beneficiaries with bipolar disorder, 2001-2004. Psychiatr Serv. 2008;59:1169-1174.
11. US FDA. Prescribing information. Seroquel XR (quetiapine fumarate) extended-release tablets [online]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022047s006s007s008lbl.pdf. Accessed September 10, 2009.
12. US FDA. Prescribing information. Seroquel (quetiapine fumarate) tablets [online]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020639s025s037s038s040lbl.pdf. Accessed September 10, 2009.
13. Jensen NH, Rodriguez RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology. 2008;33:2303-2312.
14. Altschuler EL, Kast RE. Using histamine (H1) antagonists, in particular atypical antipsychotics to treat anemia of chronic disease via interleukin-6 suppression. Med Hypoth. 2005;65:65-67.
15. Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry. 1999;4:317-327.
16. Medicine evaluation board. Public assessment report of the medicines evaluation board in the Netherland [online]. Available from: http://db.cbg-meb.nl/mri/par/nlh-0156-008-009-010-011.pdf. Accessed September 10, 2009.
17. Electronic Medicines Compendium. Seroquel Xl 50 mg, 200 mg, 300 mg, 400 mg prolonged release tablets [online]. Available from: http://emc.medicines.org.uk/medicine/21175/SPC/Seroquel%20XL%2050%20mg,%20200%20mg,%20300%20mg,%20400%20mg%20prolonged-release%20tablets/. Accessed September 10, 2009.
18. Figueroa C, Brecher M, Hamer-Maansson JE, Winter H. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:199-204.
19. Cutler A, Datto C, Nordenhem A, et al. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar mania [poster]. Presented at the 8th Annual International Review of Bipolar Disorders Conference; April 14-16, 2008; Copenhagen Denmark.
20. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression [poster]. Presented at the 8th Annual International Review of Bipolar Disorders Conference; April 14-16, 2008; Copenhagen Denmark.
21. Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 2005;66:111-121.
22. Möller HJ, Johnson S, Mateva T, et al. Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia. Int Clin Psychopharmacol. 2008;23:95-105.
23. Calabrese JR, Keck PE, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162:1351-1360.
24. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (The BOLDER II Study). J Clin Psychopharm. 2006;26:600-609.
25. Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002;159:1011-1017.
26. Yatham L, Paulsson B, Mullen J, Vagerö AM. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar Mania. J Clin Psychopharm. 2004;24:599-606.
27. Al Jurdi RK, Marangell LB, Petersen NJ, Martinez M, Gyulai L, Sajatovic M. Prescription patterns of psychotropic medications in elderly compared with younger participants who achieved a "recovered" status in the systematic treatment enhancement program for bipolar disorder. Am J Geriatr Psychiatry. 2008;16:922-933.
28. Claxton AJ, Cramer J, Pierce C. A systematic review of the association between dose regimens and medication compliance. Clin Therap. 2001;23:1296-1310.
29. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11:225-255.
30. Sajatovic M, Valenstein M, Blow F, Ganozcy D, Ignacio R. Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder. Psychiatric Services. 2007;58:855-863.
31. Perlick DA, Rosenheck RA, Kacynski R, et al. Medication non-adherence in bipolar disorder: a patient-centered review of research findings. Clinical Approaches in Bipolar Disorders. 2004;3:54-56.
32. Lingham R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002;150:164-172.